Monoclonal antibody ≈ Monoclonal antibody
View article: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Open
The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, an…
View article
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Open
Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squi…
View article
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity Open
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1…
View article
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma Open
In this trial, patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control. Greater benefits were seen in patients with hig…
View article
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease Open
BACKGROUND \nUstekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and inter-leukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease. Ustekinumab …
View article
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Open
The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral tr…
View article
Trial of Anifrolumab in Active Systemic Lupus Erythematosus Open
Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a similar phase 3 trial involving patients …
View article
Cancer immunotherapy: the beginning of the end of cancer? Open
These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include…
View article
Cold Tumors: A Therapeutic Challenge for Immunotherapy Open
Therapeutic monoclonal antibodies targeting immune checkpoints (ICPs) have changed the treatment landscape of many tumors. However, response rate remains relatively low in most cases. A major factor involved in initial resistance to ICP in…
View article
Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation Open
The outbreak of a novel betacoronavirus (2019-nCov) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for urgently needed vaccines, therap…
View article
The convalescent sera option for containing COVID-19 Open
As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).SARS-CoV-2 causes coronavirus disease, abbreviated as COVID-19.At the time of this writing, SARS-CoV-2 is spreading in mul…
View article
PD-1 <sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer Open
Significance PD-1 blockade is a cancer immunotherapy effective in various types of cancer. However, we observed rapid cancer progression, called hyperprogressive disease (HPD), in ∼10% of advanced gastric cancer patients treated with anti–…
View article
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies Open
Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain (RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) and Fabs from COVID-19 convalescent individuals for recognit…
View article
Tezepelumab in Adults with Uncontrolled Asthma Open
In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal ant…
View article
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma Open
Patients with severe, uncontrolled asthma who received tezepelumab had fewer exacerbations and better lung function, asthma control, and health-related quality of life than those who received placebo. (Funded by AstraZeneca and Amgen; NAVI…
View article
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer Open
Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consi…
View article
The making of bispecific antibodies Open
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, incl…
View article
Monoclonal Antibodies in Cancer Therapy Open
Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action. In…
View article
Pharmacokinetics of Monoclonal Antibodies Open
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and s…
View article
Antibody-drug conjugates: recent advances in conjugation and linker chemistries Open
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shif…
View article
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance Open
The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron (B.1.1.529) has ushered panic responses around the world due to its contagious and vaccine escape mutations. The essential infectivity and antibody res…
View article
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants Open
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is …
View article
Ofatumumab versus Teriflunomide in Multiple Sclerosis Open
Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).
View article
Broad neutralization of SARS-related viruses by human monoclonal antibodies Open
Seeking broad protection As scientists develop therapeutic antibodies and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the risk of emergent coronaviruses makes it important to also identify broadly protect…
View article
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics Open
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that t…
View article
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses Open
The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2–specific antibodies. Here, we describe a collection…
View article
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design Open
HIV employs multiple means to evade the humoral immune response, particularly the elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies can act antivirally against a wide spectrum of viruses by targetin…
View article
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations Open
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1), activates downstream sig…
View article
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement Open
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with earlier variants due to accumulation of numerous spike mutations. T…
View article
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 Open
Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment di…